🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
7.00
-0.46 (-6.17%)
Nov 19, 2026, 4:00 PM EST - Market closed

Orchestra BioMed Holdings Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
31.2133.482.642.763.53-0.78
Revenue Growth
1007.38%1169.22%-4.42%-21.88%--
Cost of Revenue
0.140.190.20.190.210.2
Gross Profit
31.0733.292.432.573.32-0.98
Selling, General & Admin
25.1226.9123.9320.2614.037.93
Research & Development
66.9358.1942.833.8221.9512.89
Operating Expenses
92.0485.166.7454.0835.9820.82
Operating Income
-60.97-51.81-64.3-51.51-32.66-21.8
Interest Expense
-6.55-1.9-0.3-1.4--0.93
Interest & Investment Income
0.740.753.655.250.05-
Other Non Operating Income (Expenses)
1.410.25-0.01-0.29-1.350.7
EBT Excluding Unusual Items
-65.38-52.7-60.96-47.95-33.96-22.03
Gain (Loss) on Sale of Investments
8.43--0.07-0.021.03-0.99
Other Unusual Items
----1.15-0.68-
Pretax Income
-56.95-52.7-61.02-49.12-33.61-23.01
Net Income
-56.95-52.7-61.02-49.12-33.61-23.01
Preferred Dividends & Other Adjustments
1.410.25----
Net Income to Common
-58.36-52.96-61.02-49.12-33.61-23.01
Net Income Growth
------
Shares Outstanding (Basic)
63483733152
Shares Outstanding (Diluted)
63483733152
Shares Change
51.51%29.67%10.82%121.67%609.97%4.86%
EPS (Basic)
-0.92-1.11-1.66-1.48-2.24-10.90
EPS (Diluted)
-0.92-1.11-1.66-1.48-2.24-10.90
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-64.18-49.45-50.85-46.21-29.88-19.7
Free Cash Flow Per Share
-1.01-1.04-1.38-1.39-1.99-9.33
Gross Margin
99.56%99.43%92.27%93.26%94.03%-
Operating Margin
-195.39%-154.73%-2437.49%-1866.16%-924.34%-
Profit Margin
-187.02%-158.16%-2313.27%-1779.71%-951.26%-
Free Cash Flow Margin
-205.66%-147.70%-1927.48%-1674.09%-845.74%-
EBITDA
-60.61-51.48-63.99-51.22-32.44-21.62
EBITDA Margin
-194.21%-153.75%----
D&A For EBITDA
0.370.330.310.290.220.18
EBIT
-60.97-51.81-64.3-51.51-32.66-21.8
EBIT Margin
-195.39%-154.73%----
Revenue as Reported
31.2133.482.642.763.53-0.78
SEC Filings: 10-K · 10-Q